KD025: Clinical Trials

5 trials of KD025, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed. 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 15Completed 5

Follow KD025: new trials by email Literature Review of KD025 trials Research Report on KD025

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment
KD025 - Hepatic Impairment
Phase 1CompletedKadmon, a Sanofi Company352019-12-112022-07-18
Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025
Belumosudil 200 mg tablet, [14C]-KD025 at a dose of 100 μg in a 5 mL solution IV microdose, [14C]-KD025 200 mg capsule - Autoimmune Diseases, Fibrosis
Phase 1CompletedKadmon Corporation, LLC52019-04-052022-05-26
A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects
Belumosudil mesylate, Placebo - Immune System Disorder (Healthy Volunteer)
Phase 1CompletedKadmon, a Sanofi Company82014-03-282023-06-26
A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female Subjects
Belumosudil mesylate, Placebo - Immune System Disorder (Healthy Volunteer)
Phase 1CompletedKadmon, a Sanofi Company322013-11-212023-06-26
A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male Subjects
Belumosudil mesylate, Placebo - Immune System Disorder (Healthy Volunteer)
Phase 1CompletedKadmon, a Sanofi Company322009-09-212023-06-26

Conditions studied

Immune System Diseases (3)  ·  Autoimmune Diseases (1)  ·  Fibrosis (1)

Sponsors

Kadmon, a Sanofi Company (4)  ·  Kadmon Corporation, LLC (1)

Countries

United States (4)  ·  United Kingdom (1)

Results publications

PMID 40614122

NIH funding

2018 (1)